腾盛博药生物科技有限公司（2137）于2026年2月4日公布截至2026年1月31日的月度股份变动情况。报告显示，公司注册股本本月维持1,200,000,000股，面值0.000005美元，总额6,000美元。期末已发行普通股数量（不含库存股）约为721,533,043股，较上月增加355,981股，库存股数则保持不变，为12,723,500股。
公司当月主要通过股份期权及其他股权激励计划增发股份。期权部分合计行使204,750股，涉及首发后购股权、首次公开发售股份激励等多个计划；其他股份奖励计划则新增151,231股，涵盖首次公开发售后股份奖励和2023年股份奖励计划。整体增发合计355,981股，使公司截至1月底的已发行股份（不含库存股）数升至721,533,043股。
公司同时表示，针对所有有关证券及股份的发行已遵循香港联合交易所有限公司《上市规则》和适用法规，并已获得正式授权批准。公告由联席公司秘书李安康博士签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.